To determine predictors of survival and of weaning off parenteral nutrition (PN) in pediatric short bowel syndrome (SBS) patients. Summary Background Data: Pediatric SBS carries extensive morbidity and high mortality, but factors believed to predict survival or weaning from PN have been based on limited studies. This study reviews outcomes of a large number of SBS infants and identifies predictors of success. Methods: Multivariate Cox proportional hazards analysis was conducted on 80 pediatric SBS patients. Primary outcome was survival; secondary outcome was ability to wean off PN. Nonsignificant covariates were eliminated. P Ͻ 0.05 was considered significant. Results: Over a mean of 5.1 years of follow-up, survival was 58 of 80 (72.5%) and 51 weaned off PN (63.8%). Cholestasis (conjugated bilirubin Ն2.5 mg/dL) was the strongest predictor of mortality (relative risk ͓RR͔ 22.7, P ϭ 0.005). Although absolute small bowel length was only slightly predictive, percentage of normal bowel length (for a given infant's gestational age) was strongly predictive of mortality (if Ͻ10% of normal length, RR of death was 5.7, P ϭ 0.003) and of weaning PN (if Ն10% of normal, RR of weaning PN was 11.8, P ϭ 0.001). Presence of the ileocecal valve (ICV) also strongly predicted weaning PN (RR 3.9, P Ͻ 0.0005); however, ICV was not predictive of survival.
I nfants and children with short bowel syndrome (SBS) suffer extensive morbidity and mortality. [1] [2] [3] [4] [5] SBS is generally defined as the loss (either congenital or acquired) of an extensive length of the small intestine resulting in an inadequate absorption of enteral nutrients. 6 These children are often dependent on parenteral nutrition (PN) for long periods of time, which leads to high rates of sepsis, cholestasis, and mortality. 7 Prior to the advent of PN, of course, SBS carried a dismal prognosis. 8 After dependence on PN for a variable period of time, some pediatric SBS patients demonstrate bowel adaptation and are eventually able to wean off PN. 9 -12 One early study suggested that survival in SBS required at least 15 cm of small intestine and an intact ileocecal valve (ICV) or at least 40 cm in the absence of the ICV. 9 More recently, however, these criteria have been called into question, making it difficult to determine which infants will survive, or wean off PN, without an intestinal transplant. 7, 10, 11 Risk factors thought to contribute to the high morbidity and mortality of SBS include the length of remaining small bowel, sepsis, loss of the ICV, and development of PNassociated cholestasis. [12] [13] [14] [15] Unfortunately, a major limitation in conclusively identifying these risk factors is the relative infrequency of SBS. Most previous reports on children with SBS have been limited by relatively small numbers of patients or have not used adequate statistical methods to determine which factors influence survival and the ability to wean off PN. The current study was designed to use rigorous statistical analysis of a large sample of infants with SBS to determine which factors influence SBS outcomes. In the primary analysis, we examined predictors of survival in SBS; and in the secondary analysis, we examined predictors of weaning off PN.
METHODS

Study Design
This is a retrospective review of pediatric patients with SBS treated at our institution. The study was approved by the institutional review board of the University of Michigan (IRB no. 2000-254) . Our goal was to identify predictors of survival and predictors of the ability to wean off PN. Therefore, data collected included gestational age, age at onset of SBS, etiology of SBS, small bowel length (measured at the initial operation related to SBS), presence or absence of the ICV, colonic remnant (by quartile), highest serum conjugated bilirubin, duration of PN use, and number of documented episodes of sepsis. Sepsis was defined as a positive blood culture in the setting of a clinical picture consistent with sepsis. These factors were examined as potential predictors of outcome in pediatric SBS. 9, [12] [13] [14] [15] [16] 
Inclusion Criteria
Patients were eligible for inclusion in the study if they had a clinical diagnosis of SBS, defined as loss of at least 50% of small intestinal length from surgical resection or congenital defect, or at least 2 months of PN dependence due to complete intestinal dysfunction. The majority of patients had the diagnosis of SBS within the first 6 weeks of life (n ϭ 80), with the remainder (n ϭ 13) comprising a heterogeneous assortment of etiologies in patients up to 18 years of age. Because the older patients comprised a distinctly different subset of patients than the younger group, all analyses were limited to patients Յ6 weeks of age at the time of SBS onset.
Statistical Analysis
A multivariate Cox proportional hazards regression analysis was used to model predictors of survival for the primary analysis and predictors of weaning PN for the secondary analysis. For the survival analysis, the time variable was defined as the time from onset of SBS until the time of the last follow-up for which survival was known (rightcensored cases) or until the time of death. Patients who received a small bowel transplant were considered to have failed management of SBS, and the time of last follow-up in such cases was defined as the date of transplantation. Patients were excluded from analysis after transplantation. For the analysis of weaning PN, the time variable was defined as the time from onset of SBS until the time of weaning from PN, or the last follow-up at which dependence on PN was known (right-censored cases). In the initial Cox regression model, all covariates were considered, and covariates not significantly related to the hazard of the event of interest (ie, death or weaning off PN) were identified. In subsequent Cox regres-sion modeling, these nonsignificant covariates were removed by backward elimination. Statistical analysis was performed with SPSS version 12.0 (SPSS Inc, Chicago, IL).
RESULTS
Demographics
From January 1977 through December 2003, 102 pediatric patients developed SBS, with data available for analysis in 93, of whom 80 met inclusion criteria (37 female, 43 male; Table 1 ). Patients averaged 33.0 Ϯ 4.7 weeks in gestational age (range 23-40 weeks). The etiologies of SBS represented the spectrum of congenital and acquired conditions leading to SBS in infants ( Table 1) . Duration of follow-up ranged from 66 days to 24.4 years (mean Ϯ SD, 5.1 Ϯ 5.6 years; median, 2.8 years of follow-up). Of 80 patients, 22 died (27.5%), 51 weaned off PN (63.8%, of whom 2 died), and 9 remained on PN (11.3%) (with or without some degree of enteral nutrition) at the time of last follow-up. Primary cause of death was PN-associated liver disease (n ϭ 14), sepsis (n ϭ 4), transplant failure (n ϭ 2), cardiopulmonary failure (n ϭ 1), and unknown (n ϭ 1).
Predictors of Survival
All covariates were included in the initial Cox regression model. Interestingly, gestational age, number of septic episodes, and etiology of SBS were not significant predictors of mortality. Therefore, these covariates were removed by backward elimination. The final Cox regression model, therefore, included only small bowel length, colonic length, ICV, and cholestasis as covariates (Table 2A ). Using this multivariate analysis, cholestasis was very strongly predictive of mortality ( Fig. 1 ). Patients whose highest conjugated bilirubin was Ͻ2.5 mg/dL had a survival of 94.6% (35/37 survived), whereas those with conjugated bilirubin Ն2.5 mg/dL only had a 51.2% survival (21/41 survived) (missing data, n ϭ 2). ICV and colonic remnant were not significant predictors of survival (Table 2A ). 
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Annals of Surgery • Volume 242, Number 3, September 2005 In this multivariate analysis, small bowel length per se was barely significant as a predictor of survival, with a relative risk (RR) of mortality of only 1.03 (95% confidence interval, 1.00 -1.05; P ϭ 0.04), where RR ϭ 1 indicates no effect (Table 2A) . Thus, the length of remaining small bowel seemed to have almost no impact on mortality in multivariate analysis. However, small bowel length varies with gestational age, due to rapid in utero growth. 17 Importantly, infants in this study ranged from 23 to 40 weeks' gestational age. Because small bowel length increases rapidly, more than doubling during this gestational period, 17 we questioned whether a given length of bowel in an extremely premature neonate with SBS is truly comparable to the same length of bowel in a full-term infant. Based on existing data for normal neonatal small bowel length (according to gestational age), 17 we were able to estimate what would have been the normal intestinal length for each infant in the present study and expressed the actual intestinal length as a percentage of the normal length.
A multivariate Cox regression was then performed exactly as before, except that percentage of expected small bowel length was substituted for actual small bowel length (Table 2B ). This adjusted analysis showed that remaining bowel length was actually highly significant, and very strongly predictive of survival (RR, 5.74; P ϭ 0.003; Table  2B , Fig. 2 ). Infants retaining Ն10% of their expected normal small intestinal length had an 88.1% survival (52/59 survived), whereas those with Ͻ10% of expected length had only 21.1% survival (4/19 survived; missing data, n ϭ 2). Therefore, the importance of small intestinal length as a predictor of survival only became evident after adjusting for the rapid intestinal growth which occurs during the latter half of gestation.
Furthermore, in this adjusted analysis, cholestasis continued to be the strongest predictor of mortality, with a RR of 22.7 (P ϭ 0.005, Table 2B ). This finding confirmed that cholestasis is a very strong predictor of death. Because cholestasis and small intestinal length Ͻ10% of expected are the major predictors of mortality, the combination FIGURE 1. Survival was assessed using multivariate Cox proportional hazards analysis for 80 neonatal patients with short bowel syndrome (SBS). Cholestasis (conjugated bilirubin Ն2.5 mg/dL) was highly predictive of mortality. of these 2 risk factors leads to the highest RR of death ( Fig. 3 ).
Predictors of Weaning off PN
A multivariate Cox proportional hazards regression was used to assess factors predictive of weaning off PN. Due to our findings in the survival analysis, percentage of the expected small bowel length was included as a covariate, rather than small bowel length per se. This analysis found that gestational age, etiology of SBS, and number of episodes of sepsis were not significant predictors of the ability to wean off PN. Both colonic remnant and ICV were predictive of weaning from PN, but due to an interaction effect between these covariates, only 1 could be included in the final model. Therefore, small bowel length (%), ICV, and cholestasis were included as covariates. With this analysis, 2 factors predicted the ability to wean off PN: percentage small bowel length (as the strongest predictor) and presence of the ICV (Table 3 , Figs. 4 and 5). Of 80 patients, 51 weaned off PN (63.8%) and 27 did not (33.8%) (missing data, n ϭ 2). However, only 2 out of 19 (10.5%) with Ͻ10% of expected small bowel length were able to wean, in contrast to 49 of 59 (83.1%) of those who retained Ն10% of expected small bowel length ( Fig. 4 , P ϭ 0.001). Similarly, only 19 out of 38 patients (50.0%) with no ICV weaned from PN, in contrast to 32 out of 40 (80.0%) who retained the ICV ( Fig. 5 , P Ͻ 0.0005).
Predictors of Cholestasis
Because cholestasis by far had the most profound effect on mortality, we sought to determine factors predictive of cholestasis. A logistic regression was performed, which found that small intestinal length Ͻ10% of normal was highly predictive of cholestasis. While 25 out of 59 patients (42.4%) with Ն10% of normal small intestinal length remaining did develop cholestasis, 16 out of 19 (84.2%) with Ͻ10% developed cholestasis (odds ratio, 10.36; 95% CI, 2.43-44.09; P ϭ 0.002). Although gestational age has been correlated Table 2 , that is, "risk" in Table 3 indicates patient benefit. FIGURE 2. Survival of pediatric SBS patients was stratified according to percentage of expected normal bowel length remaining (based on a subject's gestational age). Risk of mortality strongly increased in infants with Ͻ10% of the expected small intestinal length for a given gestational age.
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Body Weight and Failure to Thrive
The body weight and percentile (on standard pediatric growth charts) for patients was recorded 6 months, 1 year, and 2.5 years (or last follow-up, whichever was later) after the onset of SBS. At 6 months, 76.5% of patients demonstrated failure to thrive (body weight Ͻfifth percentile). This figure gradually diminished to 68.3% at 1 year and 47.6% at 2.5 years/last follow-up.
Surgical Therapy for SBS
Surgical procedures directed towards the treatment of SBS were recorded. Of 80 patients, 6 underwent a Bianchi bowel-lengthening procedure, 20 and 3 underwent a serial transverse enteroplasty (STEP). 21 The average bowel length prior to Bianchi was 23.7 Ϯ 5.1 cm; post-Bianchi procedure, it was 62.8 Ϯ 31.7 cm (missing data, n ϭ 1). Three patients weaned off PN post-Bianchi procedure, while 3 remained PN dependent at 2, 5, and 8 years post-Bianchi. One of these latter patients also had a STEP and remains PN dependent 2 years post-STEP. The other 2 patients who underwent STEP each gained 40 cm, resulting in 70-and 120-cm small bowel length, respectively. Both of these patients weaned off PN (17 and 12 months post-STEP, respectively).
DISCUSSION
SBS in infants and children is a complex and highly morbid condition. These patients suffer repeated episodes of sepsis, dehydration, and metabolic derangements and often require multiple hospital readmissions. 13 PN constantly demands exacting attention to detail and carries the dreaded risk of PN-associated liver disease.
Multiple studies in the literature note similar survival rates to our study. [22] [23] [24] In a recent large population-based study, the risk of death from SBS and its complications in children was 37.5%. 24 However, somewhat disappointingly, mortality rates reported here are not appreciably different from rates reported over 30 years ago. 9 It is possible that our mortality rates are affected by the inclusion of extremely premature and critically ill infants not previously considered viable and thus not included in older reports.
The current study has found that key predictors of mortality in SBS include cholestasis (conjugated bilirubin Ն2.5 mg/dL) and percentage of small bowel length. On the 
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Pediatric Short Bowel Syndrome Outcomes other hand, the number of septic episodes, presence of the ICV, and etiology of SBS were not predictive of mortality. Our data show that percentage of small bowel length (percentage of the expected length at a given gestational age), rather than the absolute length of remaining bowel, accurately predicts survival of neonates with SBS. Although the importance of remnant small bowel length has long been recognized by a number of investigators in both pediatric and adult SBS, 9, [22] [23] [24] [25] rapid elongation of the small bowel during the latter half of gestation has confounded attempts at correlating absolute small bowel length with survival in infants with SBS. This may account for the discrepancy between our findings and other reports which suggest that small intestinal length does not predict survival. 26 We found that a small bowel length Ն10% of expected for a given gestational age 17 was highly predictive of survival. The correlation is not absolute, of course, but 10% of bowel length is a strongly predictive cutoff point. Conjugated bilirubin (Ն2.5 mg/dL) is a very significant predictor of survival. This is supported by previous data. 12,26 -28 In our analysis, a conjugated bilirubin level Ն2.5 mg/dL provided the optimal sensitivity (90.9%) and specificity (62.5%) for predicting mortality.
We found that presence of the ICV and percentage of small bowel length are the primary predictors of weaning PN. There was a significantly increased likelihood that patients who retained the ICV would be weaned from PN. The ileum has greater adaptability after bowel resection than more proximal intestinal segments, which may explain its importance in weaning off PN. 10,29 -31 Alternatively, absorptive function of the remaining colon may contribute to adaptation after small bowel loss. 30 It was not possible to distinguish the effects of reduced colonic length versus loss of the ICV, due to the strong correlation between these 2 covariates for obvious anatomic reasons. Clearly, the ICV will also delay small bowel transit and may improve absorption. 31, 32 Although an improvement in the ability to wean PN in patients with greater small intestinal length has been reported, 25, 33 our data provide additional support for this concept.
It was interesting to note that the only factor correlating with the development of cholestasis was percentage of predicted small bowel length. Terra et al 34 suggested that small bowel remnants less than 50 cm correlated with catheter sepsis and bacterial translocation. As both of these latter complications may exacerbate cholestasis, reduced bowel length may contribute indirectly to development of cholestasis.
The striking incidence of failure to thrive in our SBS population was concerning. It suggests that we may not be adequately supporting our SBS infants, although overfeeding is also fraught with complications. In a smaller study of 16 pediatric patients on long-term PN, failure to thrive was a significant problem (12 of the 16) and may have been attributable to a lack of adequate protein supplementation. 35 In summary, cholestasis (conjugated bilirubin Ն2.5 mg/dL) and small bowel length Ͻ10% of expected length are the main predictors of death in this patient population. In addition, weaning of the SBS patient off PN was examined. For this secondary outcome, presence of the ICV and small bowel length Ն10% of expected length were significant predictors. These data may improve clinicians' ability to assess the need for intestinal transplantation earlier in the course of SBS. DR. DANIEL H. TEITELBAUM (ANN ARBOR, MICHIGAN): I don't have anyone with quite that long a follow-up. My experience is more limited. But our clinic certainly has continued to bring in patients through Dr. Coran for the past 30-odd years, and what is evident is that these patients, once they are diagnosed with short bowel syndrome, even if they wean from parenteral nutrition, have life-long issues that they carry with them. I am often amazed how many nutritional and digestive problems they carry with them that are not picked up or sufficiently diagnosed. Your particular problem, though, I haven't encountered.
Discussions
DR. ROBERT J. TOULOUKIAN (NEW HAVEN, CONNECTICUT):
Dr. Teitelbaum and his colleagues in this elegant study on pediatric short bowel syndrome have used statistical analysis of over a hundred of their cases to redefine predictors of successful treatment. In doing so, they have actually reconfirmed the work of Douglas Wilmore, a member of this Association, who showed in 1972, literally only 3 years following the introduction of total parenteral nutrition, that the criteria for survival for full-term infants having major intestinal resection was 15 cm with the ileocecal valve present or 5% of estimated total intestinal length for full-term infants and 40 cm or 13% of residual bowel length in the absence of the ileocecal valve.
As has been pointed out by the authors, absolute residual length measurements are no longer a useful predictor of survival since nearly half of all pediatric short bowel patients are infants with operations for necrotizing enterocolitis having a birth weight of 1,500 grams or less and a gestation rate below 30 weeks, a situation which was unheard of in the early 1970s.
I have a couple of questions regarding the inclusion criteria used in the study. The patients in the study were accrued from 1977 to the present time where treatment modalities, including safety issues with TPN, the choice of antibiotics and ventilator management to name just a few, are known to be highly significant predictors of survival for intact nonoperated babies with necrotizing enterocolitis. A breakdown of the statistical analysis for an early and a late group in a 26-year retrospective study would be vital to determine which other time-related factors may influence outcome.
The second question is: What definition is used for short bowel syndrome as the indicator for inclusion in the study? The authors state in their manuscript that the definition of short bowel syndrome varies widely amongst clinicians. But I believe it is more than a "extensive loss of the small bowel resulting in an inadequate absorption of enteral nutrients." In a retrospective study such as this one, a minimum time of TPN support, such as three months for example, should be used as the entry point for further study of outcome. I would ask the authors what minimum time requirement for TPN was used in their initial definition of short bowel syndrome? Despite enormous advances in neonatology and the surgical care of small infants requiring major bowel resection, cholestatic liver disease is not much better understood now than shortly following the introduction of TPN.
Dr. Teitelbaum correctly points out that elevated conjugated bilirubin above 2.5 milligrams percent is a significant predictor of mortality. What was of interest to me is that prematurity alone is not an independent variable for predict-ing death or severe cholestasis in this study, a finding I had not previously thought to be true.
What we have learned is that reconstituting the residual bowel remnants to maximize length by early take-down and closure of the stomas and ensuring against surgical complications by meticulous technique in the constructing of the anastomoses gives the best chance to prevent TPN cholestasis. I would ask the authors if complications related to the wound and anastomosis and the time when the GI tract was finally reconstituted were studied and did that influence outcome? As surgeons we continue to be the principal variable in outcome by understanding the timing of operation, the choice of the procedure, the judgment on how much bowel to resect, and how rigorous we are in attempting to preserve the ileocecal valve.
DR. DANIEL H. TEITELBAUM (ANN ARBOR, MICHIGAN):
Would there be a difference in outcomes if you look at some of the patients that were treated early versus late? As I said, I think, in the talk, 90% of our patients were less than a year of age when diagnosed with short bowel syndrome. So the bulk of our patients really came over the past 10 years. We did have some older patients that were born as early as 1977 and that did skew a few of our patients to a little bit older range. There is not a specific difference in survival in these patients treated earlier versus late.
I think what is even more dramatic, as you alluded to Dr. Wilmore's study in 1972, the survival rate in that group of patients is actually not significantly different than our survival of 27%. In some ways it is sort of sad that we have not really progressed that much in our overall mortality rate, but we are taking on a much more complex group of patients than in the early '70s.
Our definition of short bowel syndrome was 70% of small bowel length. When you mentioned the duration of TPN, it is important to keep in mind that we included all patients with short bowel syndrome globally, and so there were a few patients that were on for less than 3 months that actually died secondary to TPN-related cholestasis that rapidly progressed early in their course.
Finally, we did not look at specific wound complications and whether they greatly impacted the overall care. I would say parenthetically that these kids are very delicate, infants in particular, and there is sort of a race against time in these particular patients to get continuity of their bowel intact, close their ileostomies and have them start utilizing their gut to prevent them from developing TPN-associated cholestasis. And certainly having a wound infection and the like would significantly impact adversely those particular patients.
DR. MARSHALL Z. SCHWARTZ (PHILADELPHIA, PENNSYLVANIA): I would like to congratulate Dr. Teitelbaum and his col-leagues for addressing what is a major issue in the pediatric age group. The morbidity from short bowel syndrome in the pediatric age group is significant with frequent hospitalizations mostly related to the complications of parenteral nutrition and the catheters that we use to deliver the nutrition. In addition, as Dr. Teitelbaum has alluded to, the cost of this management is significant. The numbers that Dr. Teitelbaum stated are probably rather low, because if you extrapolate these costs out for a few years you are well into millions of dollars per infant and increasing as long as they survive.
This study was initiated to assess the factors that impact mortality in patients with short bowel syndrome and especially those associated with parenteral nutrition. The investigators concluded that cholestasis was the most significant correlate. But in the presentation we heard that bowel length also is a significant factor in survival. I believe that it is an important finding that, based on postnatal age and gestational age, that there is a correlation with the percent of lost intestine.
I have the following questions: I was a little surprised that the diagnosis was not a predictive factor, and I am particularly referring to gastroschisis. In my experience, infants that have had an in utero vascular occlusion related to gastroschisis resulting in loss of most of their midgut, that the residual bowel does not work very well regardless of how long it is. Did you specifically look at that issue?
Secondly. The mortality was based on cholestasis. However, are you referring to cholestasis or is this fibrosis as a result of cholestasis? Many of these infants do not get into trouble with liver disease until 6 months of age, but they may have had cholestasis much earlier.
Finally, you have done extensive work on the relationship of cholestasis to short bowel syndrome. From that work, have you altered how you manage infants with cholestasis on parenteral nutrition and has that had an impact on lowering their liver enzymes or direct bilirubin?
One last comment. In the end, you had the same conclusion, that is, to preserve the ileocecal valve and to try to retain as much bowel length as possible despite apparent lack of a relationship with cholestasis. I wonder if you might comment about this further.
DR. DANIEL H. TEITELBAUM (ANN ARBOR, MICHIGAN): I think going into the analysis I did have a preconceived notion that my gastroschisis patients would do worse just for the reasons you mentioned: it is an ischemic-related event. Nevertheless, when we did the analysis that did not work. As we have talked about before, perhaps with a larger group, with multiple centers contributing their data, it may be beneficial in getting at that particular question better. Even with a hundred patients, that may still not be enough to answer that particular question.
With regard to mortality, clearly cholestasis may complicate the course of a patient and the hospital may predispose them to infections or other complications. But it is truly the progression of cholestasis to liver fibrosis that will result in these patients' deaths. And that is, unfortunately, not always in a predictable fashion. There are some patients that may take several months to develop that particular course and there are some patients that actually progress much more quickly.
You asked how we could treat cholestasis, or how we have changed our approach in treating this. And I don't have any good answers. This coming month a paper is coming out from our group where we have tried to look at the use of cholecystokinin to prevent the development of cholestasis in these particular patients. And despite looking at almost 250 patients, we failed to find efficacy in using that particular hormone.
We have also tried eliminating or decreasing the amount of lipids in our patients. Although I do think it is somewhat radical I have seen some fairly dramatic declines in hyperbilirubinemia in patients treated with a course of steroids. That has to be used pretty cautiously because obviously that has an immunosuppressive effect on these patients who are predisposed to infections.
DR. PAUL R. SCHLOERB (KANSAS CITY, KANSAS): My interest is in the type of parenteral nutrition used. Several years ago we surveyed TPN usage in 103 academic medical centers and found that about three-quarters of them were using excessive amounts of glucose. Based upon one pediatric patient of Dr. William Buntain, a pediatric surgeon in Kansas at the time, she was born with little small bowel and large bowel and had a Martin procedure with a side-to-side anastomosis. The child did very well for 14 months using an amount of glucose which was 12 grams per kilogram calculated body cell mass per day. Using this formula over a period of several years, we have not observed the fatty liver complications so often associated with TPN. So I would like to ask: What were the constituents of your parenteral nutrition solution?
DR. DANIEL H. TEITELBAUM (ANN ARBOR, MICHIGAN): I think that everybody has speculated on one particular substrate in parenteral nutrition that may be a cause of cholestasis. And there isn't any firm answer. I think clearly limiting the amount of glucose or dextrose that one administers is important only in that you obviously do not want to overfeed these patients. Because overfeeding them is going to result in hepatic steatosis, which will worsen one's liver condition.
At the beginning of our series we actually treated our patients with an adult amino acid-type formulation and toward the end, the latter 7 to 10 years, we utilized a pediatric formulation which has taurine supplemented in it. And in a separate study we were able to demonstrate quite accurately that just the supplementation of taurine in these patients was able to significantly decrease the incidence of TPN-related cholestasis.
DR. JEAN C. EMOND (NEW YORK, NEW YORK): This is very elegant both as an organizational system for caring for patients with gut failure as well as a very fine statistical analysis. I wanted to ask you, though, about the issue of integration of all this care with transplant candidacy. We heard yesterday about a hundred multivisceral transplants. Many of us suspect that a lot of those transplant patients had livers that could recover or had preventable liver disease with optimal care, while some of those intestines would have probably been okay.
What is your philosophy about how to integrate transplant care with intestinal failure care? Twenty years ago biliary atresia care was separated into transplant camp and the Kasai camp and now we have come together. Have you developed an integrated approach that involves evaluation for intestine or liver transplant?
That is a very good question. I don't have a precise answer. Obviously, with every decision you make there is a risk and benefit that you have to weigh, which is why I showed that one slide that showed the relative risk of combining two bad hits-a child cholestasis plus very reduced small bowel length. I think you can make a poor judgment both ways at times. And I have certainly miscalled and not sent a patient for an intestinal transplant soon enough and had that child expire.
Conversely, once you generally send a patient to a transplant center, it is set that the child will be transplanted. I do think that has changed somewhat, and many centers are much more cautious now. So I have tended to be a little bit more aggressive than I have maybe several years ago because I do feel that the outcomes are improved. But I think that this particular type of data may help make that decision and help one sort that out. DR. J. ALEX HALLER, JR. (BALTIMORE, MARYLAND): Dr. Teitelbaum, you have now given us a lot of new information; and in keeping with our evidence-based surgery approach, I would extend some of the other questions to ask you if you are in any way changing your immediate decision in the operation for the initial episode that is causing the short bowel syndrome.
Many of us over the years have had to close newborn babies with midgut volvulus where all the bowel is dead, then talking with parents and having a second look perhaps, and that decision was made more or less for us. But nevertheless, now we have your new data. And if I understand correctly, fully 61% of these patients with short bowel syndrome had their short bowel condition determined before 2 weeks of age. Clearly a decision could have been made that these babies were, in a sense, miscarriages at that point, since they were also largely premature.
Have you included that approach into your management of these patients? We all know there are things worse than death when you are a newborn baby. Since we have a long track record of making this kind of decision for extensive midgut volvulus; and as we all know, the gastroschisis baby has actually also midgut volvulus likely as a part of the short bowel syndrome, have you changed your management in keeping with this information rather than prolonging the lives of children who are going to be costly to themselves, not to speak to the cost to the family? DR. DANIEL H. TEITELBAUM (ANN ARBOR, MICHIGAN): I think that is an excellent question. Because clearly for one to really attain a successful outcome even if that child needs a transplant, that child needs to be alive and surviving for some period of time. It may not be so much that I would change my approach, but probably have a more realistic outlook to some of our patients that have virtually no small bowel at all. In some of those patients, not doing anything may be the wiser choice in that regard. That is clearly a judgment call and rather difficult to make except on a case-by-case basis, but I think it is an excellent point.
